An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) has postponed its 2022 Half-Year Results release from September 22, 2022, to no later than October 31, 2022. This delay is due to the allocation of management resources towards implementing a joint venture with Tasly Pharmaceutical. The company will announce a new financial calendar shortly.
Mauna Kea Technologies develops Cellvizio®, a platform for real-time in vivo cell imaging, which is crucial for disease monitoring and surgical guidance.
Positive
Ongoing joint venture with Tasly Pharmaceutical, potentially enhancing business growth.
Negative
Postponement of 2022 Half-Year Results may raise investor concerns about management's focus and resource allocation.
PARIS & BOSTON--(BUSINESS WIRE)--
Regulatory News:
Mauna Kea Technologies(Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY), inventor of Cellvizio®, the multi-disciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, postpones release of its 2022 Half-Year Results, which was originally planned for September 22, 2022, to not later than October 31, 2022.
The delay reflects the diversion of management resources as required to implement the Company’s previously announced joint venture with Tasly Pharmaceutical.
The company will release its new financial calendar shortly.
About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and markets Cellvizio®, the real-time in vivo cell imaging platform. This technology provides unique in vivo cellular visualization that allows physicians to monitor disease progression over time, assess responses as they occur, classify areas of uncertainty and guide surgical interventions. The Cellvizio platform is used in many countries around the world and in several medical specialties and is transforming the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.
Disclaimer
This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Techonologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 3 of Mauna Kea Technologies' 2020 Universal Registration Document filed with the Autorité des marchés financiers (AMF) on June 17, 2021 under number D-21-0566 and the amendment to the Universal Registration Document filed with the AMF on September 17, 2021, both of which are available on the Company's website (www.maunakeatech.fr ), as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.
